Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2024

04.01.2024 | Editorial

Thyrotoxicosis is no insurance against thyroid cancer

verfasst von: Sabina Dizdarevic, V. Ralph McCready, Mirza Skalonja

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Excerpt

The thyroid gland was one of the original organs studied using a radionuclide. The uptake and distribution of radioiodine reflect the thyroid metabolism and pathophysiology of both benign and differentiated malignant thyroid tissue. This has enabled imaging and successful therapy of benign and malignant conditions with the same radionuclide [1]. …
Literatur
1.
McCready R. Radioiodine – the success story of nuclear medicine: 75th anniversary of the first use of Iodine-131 in humans. Eur J Nuc Med Mol Imaging. 2016;44:179–218.CrossRef
2.
3.
Rossi ED, Pantanowitz L, Hornick JL. A worldwide journey of thyroid cancer incidence centred on tumour histology. Lancet Diabetes Endocrinol. 2021; 9193–194.
4.
Lim H, Devesa SS, Sosa JA, Check D, Kithara, Cari M. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017;317:1338–1348.
5.
6.
De Villalonga B, Volpi F, Chumbiauca E, García M, Guillen-Grima F, Galofré JC. The incidence of thyroid cancer in Europe: a meta-analysis. Endocrine Abstracts. 2023: 92 PS2–16–03 | https://​doi.​org/​10.​1530/​endoabs.​92. PS2–16–03.
7.
8.
Stocker DJ, Burch HB. Thyroid cancer yield in patients with Graves’ disease. Minerva Endocrinol. 2003;28:205–12.PubMed
9.
Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves’. Am J Surg. 2006;191:400–5.CrossRefPubMed
10.
Arosemena MA, Nicole A, Cipriani NA, Dumitrescu AM. Graves’ disease and papillary thyroid carcinoma: case report and literature review of a single academic center. BMC Endocr Disord. 2022;22:199.CrossRefPubMedPubMedCentral
11.
Kamran SC, Marqusee E, Kim MI, Frates MC, Ritner J, Peters H, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab. 2013;98:564–70.CrossRefPubMed
12.
Kikuchi S, Noguchi S, Yamashita H, Kawamoto Uchino S. Prognosis of small thyroid cancer in patients with Graves’ disease. Br J Surg. 2006;93(4):434–9.CrossRefPubMed
13.
Links TP, van Tol KM, Jager PL, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273–80.CrossRefPubMed
14.
Sundaraiya S, Dizdarevic S, Miles K, Quin J, Williams A, Wheatley T, et al. Unusual initial manifestation of metastatic follicular carcinoma of the thyroid with thyrotoxicosis diagnosed by Tc 99m pertechnetate scan: case report and review of literature. Endocr Pract. 2009;15(5):458–62.CrossRefPubMed
15.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–421.CrossRefPubMed
16.
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. European Thyroid Association guideline for the management of graves’ hyperthyroidism. Eur Thyroid. 2018;7(4):167–210.CrossRef
17.
Lacey NA, Jones A, Clarke SE. Role of radionuclide imaging in hyperthyroid patients with no clinical suspicion of nodules. Br J Radiol. 2001;74(882):486–986.CrossRefPubMed
18.
Ito Y, Miyauchi A, Kithara M, Fukushima M, Higashiyama TA. Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World Journal Surgery. 2018;42:615–22.CrossRef
19.
Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. Endocrineol Metab Clin North Am. 1990;19(3):593–612.CrossRef
20.
Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am. 1998;27(1):169–85.CrossRefPubMed
21.
Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nuc Med Mol Imaging. 2019;46:2514–25.CrossRef
22.
Tamatea JA, Tuakoi K, Conaglen JV, Elston MS, Meyer-Rochow GY. Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? ANZ J Surg. 2014;84:231–4.CrossRefPubMed
23.
Fu H, Cheng L, Jin Y, Chen L. Thyrotoxicosis with concomitant thyroid cancer. Endocr Relat Cancer. 2019;26:395–413.CrossRef
Metadaten
Titel
Thyrotoxicosis is no insurance against thyroid cancer
verfasst von
Sabina Dizdarevic
V. Ralph McCready
Mirza Skalonja
Publikationsdatum
04.01.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-023-06580-y

Weitere Artikel der Ausgabe 6/2024

European Journal of Nuclear Medicine and Molecular Imaging 6/2024 Zur Ausgabe

Editorial

PET imaging of PD-L1 with a small molecule radiotracer

Original Article

First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody

Image of the Month

[18F]F-AlF-NOTA-octreotide PET/CT detected the [18F]FDG negative ectopic ACTH tumor in mediastinum

Original Article

2-[18F]FDG PET-based quantification of lymph node metabolic heterogeneity for predicting lymph node metastasis in patients with colorectal cancer

Original Article

Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin αvβ3

Original Article

The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease